Eleven Biotherapeutics Named One of the “Fierce 15” Leading Biotech Companies of 2010

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Eleven Biotherapeutics, a biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, announced today that FierceBiotech has named Eleven Biotherapeutics as one of 2010’s “Fierce 15,” designating it as one of the most promising biotech companies in the industry.

“The single most valuable asset at Eleven Biotherapeutics is the brainpower being brought to the table by a group of distinguished scientists and a pack of aggressive venture players who are pioneering a new generation of protein therapeutics,” said John Carroll, editor of FierceBiotech. “Teamed with a pair of deep-pocket venture groups and headed by Third Rock’s Mark Levin – the former Millennium chief who once again is donning the cap of interim CEO of a startup biotech company – Eleven has its platform technology up and running, with plans to start striking collaboration deals in the new year.”

Every year, FierceBiotech evaluates hundreds of private companies for its annual list, which is based on a variety of factors such as the strength of its technology, partnerships and a competitive market position. A complete list of “Fierce 15” companies is available online at www.fiercebiotech.com.

“There is a clear need for a new generation of protein engineering companies, and Eleven’s drug programs are uniquely positioned to address unmet needs for a range of diseases, such as inflammatory conditions and coagulation disorders,” said Mark Levin, interim chief executive officer and board member of Eleven Biotherapeutics, and partner, Third Rock Ventures. “Inclusion in this year’s ‘Fierce 15’ is an honor that highlights the strength of Eleven’s strong scientific foundation and differentiated approach to developing protein-based therapeutics.”

About Eleven Biotherapeutics

Eleven Biotherapeutics is focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics to improve human health and treat disease. Eleven Biotherapeutics' scientists are engineering protein-based drugs using newly available structural information and the company’s unique molecular understanding of clinical effects to create the next generation of protein-based medicines to treat important diseases with unmet needs, such as inflammatory conditions and coagulation disorders. The Cambridge, Mass.-based company is backed by top-tier life science investors Flagship Ventures and Third Rock Ventures. For more information, please visit www.elevenbio.com.

About FierceBiotech

FierceBiotech is the biotech industry's daily monitor - a free email newsletter and web resource providing the latest biotech news, articles, and resources related to clinical trials, drug discovery, FDA approval and regulation, biotech company deals and more. More than 75,000 top biotech professionals rely on FierceBiotech for an insider briefing on the day’s top stories. Sign up is free at http://www.fiercebiotech.com.



CONTACT:

Pure Communications, Inc.
Dan Budwick, 973-271-6085

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Technology  Internet  Health  Biotechnology  Pharmaceutical  Manufacturing  Engineering

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.